Zolmitriptan

Zolmitriptan 구조식 이미지
카스 번호:
139264-17-8
상품명:
Zolmitriptan
동의어(영문):
Zomig;Zomi;311c90;bw311c90;Zolmitrptan;zolmitripan;Zolmitriptan;ZOLMITRIPTANE;ZOLIMITRIPTAN;Zuomi quputan
CBNumber:
CB3313219
분자식:
C16H21N3O2
포뮬러 무게:
287.36
MOL 파일:
139264-17-8.mol
MSDS 파일:
SDS

Zolmitriptan 속성

녹는점
136-141°C
알파
D22 -5.79° (c = 0.5 in methanol)
끓는 점
563.3±38.0 °C(Predicted)
밀도
1.217±0.06 g/cm3(Predicted)
저장 조건
15-25°C
용해도
5mg/ml의 DMSO에 용해됨
산도 계수 (pKa)
9.64(at 25℃)
물리적 상태
가루
색상
흰색에서 베이지색
optical activity
[α]/D -3 to -8°, c = 1 in methanol
최대 파장(λmax)
225nm(lit.)
Merck
14,10189
안정성
제공된 대로 구매일로부터 2년 동안 안정적입니다. DMSO 용액은 -20°C에서 최대 3개월 동안 보관할 수 있습니다.
InChIKey
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
CAS 데이터베이스
139264-17-8(CAS DataBase Reference)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 Xi,Xn
위험 카페고리 넘버 36/37/38-22
안전지침서 26-36
WGK 독일 3
RTECS 번호 RQ2707000
HS 번호 29349990
독성 women,TDLo,oral,6mg/kg/43W-I (6mg/kg),BEHAVIORAL: HEADACHE,Lancet. Vol. 353, Pg. 378, 1999.
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H302 삼키면 유해함 급성 독성 물질 - 경구 구분 4 경고 GHS hazard pictograms P264, P270, P301+P312, P330, P501
예방조치문구:
P264 취급 후에는 손을 철저히 씻으시오.
P264 취급 후에는 손을 철저히 씻으시오.
P270 이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.
P501 ...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
2 0

Zolmitriptan MSDS


(4R)-4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one

Zolmitriptan C화학적 특성, 용도, 생산

개요

Zolmitriptan is a selective serotonin receptor agonist of the 1B and 1D subtypes. It is mainly used in the acute treatment of migraine attacks with or without aura and cluster headaches. Zolmitriptan takes effect through binding to human 5-HT1Band 5-HT1Dreceptors, leading to cranial blood vessel constriction and the release of sensory neuropeptides through nerve endings in the trigeminal system.

화학적 성질

White Crystalline Powder

용도

Zolmitriptan is a serotonin 5HTID-receptor agonist and used to treat migraine (1,2,3).

일반 설명

Zolmitriptan, the second triptan marketed (approved in1997), has a much better bioavailability (40%–48%) thansumatriptan. It is rapidly absorbed after oral or nasal sprayadministration. It also has an orally disintegrating tablet formulation(Zomig ZMT), which can be taken without water.Zolmitriptan undergoes rapid N-demethylation via CYP1A2to a more potent, active metabolite, N-desmethylzolmitriptan,which is 2 to 6 times more potent than the parentdrug. This active metabolite was detected 5 minutesafter dosing and accounts for about two thirds of the plasmaconcentration of the administered dose of the parent drug.284Thus, it is reasonable to assume that the therapeutic effectsand especially the CNS side effects of zolmitriptan must bein part attributed to the plasma levels of this active metabolite,at least until it is further degraded by hepatic MAO-Ato its inactive indole acetic acid derivatives.

Clinical Use

Zomig was launched in Germany, Denmark, Sweden and the UK for use as an antimigraine agent (with and without aura). It can be prepared by three related routes of 5 to 7 steps starting from L-4-nitrophenylalanine. Zomig is a 5-HT1D/1B receptor agonist (10 fold ratio) with modest (< 100x) affinity for 5-HT1A and 5-HT1F receptors. It has no affinity for other serotonin receptors or receptors of other neurotransmitters. It has a novel dual action mechanism: centrally it acts on the trigeminal nucleus caudalis and peripherally is acts on the trigeminovascular system. Zomig was effective in treating headaches and nonheadache (photophobia, phonophobia and nausea) symptoms. It was 2-3 times more potent than sumatriptan and is metabolized to three compounds, one of which is 2-8 times more active than the parent. It caused a 40-50% decrease in headache after 1 h and a 73-77% after 4 h. There was a 30% reoccurance of headache but 90% effective treatment with a second dose. It blocks neurogenic inflammation by inhibiting release of peptides, causes vasoconstriction, and inhibits neuronal depolarization at peripheral sites in the cranium. It is 40% bioavailable and a 10 time theraputic dose showed no safety concerns.

참고 문헌

https://www.drugbank.ca/drugs/DB00315
Rothner, A. D., et al. "Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents." Headache the Journal of Head & Face Pain 46.1(2006):101.
Hedlund, C, et al. "Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies. " Neurology49.9(2009):1315–1323.

Zolmitriptan 준비 용품 및 원자재

원자재

준비 용품


Zolmitriptan 공급 업체

글로벌( 515)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Shandong Hengshannuode Pharmaceutical Technology Co., Ltd.
+8615065888978
admin@hsnordpharma.com China 92 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177
peter@yan-xi.com China 6011 58
Sinoway Industrial co., ltd.
0592-5800732; +8613806035118
xie@china-sinoway.com China 992 58
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971 +86-17331933971
deasea125996@gmail.com China 2503 58
Zibo Hangyu Biotechnology Development Co., Ltd
+86-0533-2185556 +8617865335152
Mandy@hangyubiotech.com China 11013 58
Hebei Zhuanglai Chemical Trading Co.,Ltd
+8613343047651
admin@zlchemi.com China 2852 58
Hebei Shengyang Water Conservancy Engineering Co., Ltd.
+8615373025980
clara@hbshengyang.com China 783 58
Nanjing Gold Pharmaceutical Technology Co. Ltd.
025-84209270 15906146951
CHINA 115 55
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21687 55
Shanghai Time Chemicals CO., Ltd.
+86-021-57951555 +8617317452075
jack.li@time-chemicals.com China 1807 55

Zolmitriptan 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved